CClinicalTrials.gg
CompletedNCT01145547Updated Oct 23, 2015Results posted

Continuous Glucose Monitoring to Measure Effect of Glycemic Index

An interventional study of Dexcom Seven® Plus Continuous Glucose Monitoring sensor in Type 1 Diabetes Mellitus, sponsored by Legacy Health System. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2015-10-23.

Sponsored by Legacy Health System · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Randomized
Sex
All
01

Study summary

Background: Post-prandial hyperglycemia is common in people with type 1 diabetes.

Objective: The aim was to determine the impact of low vs high glycemic index (GI) on post-prandial glycemia for breakfast vs lunch and to quantify these effects with continuous glucose monitoring.

Design: Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low GI; in the other, high GI. Meals were given 195 minutes apart and were matched for carbohydrate, protein, and fat content. Each subject received his usual pre-prandial insulin dosage, followed by a continuous subcutaneous basal insulin infusion for the remainder of the experiment. Arterialized venous glucose was analyzed every 15 minutes and sensor glucose was recorded every 5 minutes.

Read the detailed description

A total of 14 diet studies (each with two meals) were completed in three men and four women. All subjects completed two diet studies in which two meals were served 195 minutes apart. On one study day, two high GI (> 75) meals were given, and on the other study day, two low GI (\< 30) meals were given. The low GI and high GI meals were matched for amount of carbohydrates, protein, and fat based on a weight-maintaining diet for each subject. The order of the study treatment (high or low GI) was randomized. Subjects were not informed as the GI of any meal.

02

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • glycemic index
  • Diabetes Mellitus
  • continuous glucose monitoring
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 7 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Legacy Health System is the lead sponsor of 30 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • clinical diagnosis of type 1 diabetes mellitus
  • patients on insulin pump therapy

Exclusion Criteria:Any patient who was

  • pregnancy
  • cardiovascular, cerebrovascular, kidney, or liver disease
  • uncontrolled chronic medical conditions
  • oral or parenteral corticosteroid use
  • immunosuppressant use
  • visual or physical impairments that impede the use of a continuous glucose monitoring device
  • insulin or glucagon allergy
  • hypoglycemia unawareness
  • requirement of greater than 200 units of insulin per day
  • gastroparesis
  • any prior gastric surgery
  • an allergy to any food items served.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
7 participants (actual)

Study arms

  • Active comparator
    low glycemic index effect on post-prandial peak

    Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.

    Device: Dexcom Seven® Plus Continuous Glucose Monitoring sensor

  • Active comparator
    high glycemic index effect on post-prandial peak

    Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.

    Device: Dexcom Seven® Plus Continuous Glucose Monitoring sensor

Interventions

  • DeviceDexcom Seven® Plus Continuous Glucose Monitoring sensor

    A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Curve for Rise in Breakfast Post-prandial.

    Arterialized blood glucose was monitored at 15 minute intervals and sensed glucose was recorded at five minute intervals. Mean area under the curve was calculated over the 3 hour period after breakfast for both the high and low glycemic breakfast meals.

    Time frame: Mean area under the curve was calculated at 0, 15min, 30 min, 45 min, 60min, 75 min, 90 min, 105 min, 120min, 135min, 150min, 165min and 180 min after breakfast

07

Results

Posted Oct 5, 2015

Participant flow

Seven subjects with Type 1 diabetes mellitus on subcutaneous insulin pump therapy were recruited from clinics in Portland, Oregon, USA.

Participant flow — Overall Study
MilestoneLow Glycemic Index, High Glycemic IndexHigh Glycemic Index, Low Glycemic Index
Started43
Completed43
Not completed00

Outcome measures

PrimaryMean Area Under the Curve for Rise in Breakfast Post-prandial.

Arterialized blood glucose was monitored at 15 minute intervals and sensed glucose was recorded at five minute intervals. Mean area under the curve was calculated over the 3 hour period after breakfast for both the high and low glycemic breakfast meals.

Time frame:
Mean area under the curve was calculated at 0, 15min, 30 min, 45 min, 60min, 75 min, 90 min, 105 min, 120min, 135min, 150min, 165min and 180 min after breakfast
Reported as:
Mean · min x (mmol/l)
Mean Area Under the Curve for Rise in Breakfast Post-prandial.
min x (mmol/l)Low Glycemic Index Effect on Post-prandial PeakHigh Glycemic Index Effect on Post-prandial Peak
Mean Area Under the Curve for Rise in Breakfast Post-prandial.61 ± 135583 ± 113

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Glycemic Index Effect on Post-prandial Peak—0/7 (0%)0/7 (0%)
High Glycemic Index Effect on Post-prandial Peak—0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years7
>=65 years0
Age, Continuous
Age, Continuous(years)All Study Participants
Mean45 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female4
Male3
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States7
08

Study locations

1 site
  • Legacy Health System--Holladay Park Campus
    Portland, Oregon 97232, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01145547
Lead sponsor
Legacy Health System
Collaborators
Juvenile Diabetes Research Foundation
Responsible party
W. Kenneth Ward (Senior Scientist, Legacy Health System) — Principal investigator
First posted
Jun 16, 2010
Start date
Apr 2009
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Oct 5, 2015
Last update
Oct 23, 2015

Study contacts

W K Ward, MD
principal investigator · Legacy Health System

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion